aaiPharma Added to Nasdaq Biotechnology Index

aaiPharma Added to Nasdaq Biotechnology Index 


WILMINGTON, N.C., Nov. 24  /PRNewswire-FirstCall/ -- aaiPharma Inc. , a
science-based specialty pharmaceutical company, announced that the Company has
been added to the Nasdaq Biotechnology Index  effective today, November 24,
2003.

"This listing is a testament to aaiPharma's strong financial position and
continued execution of the Company's science-based specialty pharmaceutical
strategy," said Dr. Philip S. Tabbiner, President and CEO of aaiPharma.

Launched in 1993, the Nasdaq Biotechnology Index contains companies that are
classified according to the FTSE(TM) Global Classification System as either
biotechnology or pharmaceutical. The Nasdaq Biotechnology Index is calculated
under a modified capitalization-weighted methodology. All securities in the
Index are listed on the Nasdaq National Market and meet minimum requirements,
including market value, average daily share volume, and seasoning as a public
company. The Index is ranked on a semi-annual basis in May and in November, and
serves as the basis for the iShares Nasdaq Biotechnology Index Fund(SM) (IBB).

About aaiPharma

aaiPharma Inc. is a science-based specialty pharmaceutical company with more
than 23 years of drug development experience. Focusing on targeted therapeutic
areas, the Company markets a growing portfolio of established branded products
and applies innovative technologies to increase the commercial potential of
these products. At the same time, aaiPharma's research and development
organization is developing a pipeline of products to position the Company for
near-term and long-term growth in its targeted therapeutic areas. In addition to
developing and marketing its own line of proprietary pharmaceutical products,
aaiPharma continues to be a leader in providing contract pharmaceutical
development services through its AAI Development Services division.  For more
information on the Company, please visit us on the web at
http://www.aaipharma.com/. 

DATASOURCE: aaiPharma Inc.



CONTACT:  media, Andrea L. Johnston, Vice President, Corporate

Communications, [phone], or investors, James B. Sloan, Jr.,

Senior Vice President, Corporate Finance, [phone], both of

aaiPharma Inc.



Web site:  http://www.aaipharma.com/ 

Copyright